1. Home /
    2. Altai Protocol Library /
  2. New Reference: Sacituzumab govitecan for metastatic triple-negative breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Reference: Sacituzumab govitecan for metastatic triple-negative breast cancer

New Reference: Sacituzumab govitecan for metastatic triple-negative breast cancer
Study:
  • Open-label, randomized phase III trial (ASCENT)
  • Metastatic triple-negative breast cancer, relapsed or refractory to >=2 regimens (had to include a taxane)
  • Sacituzumab govitecan (n=235) vs. single-agent chemotherapy [eribulin, vinorelbine, capecitabine, gemcitabine] (n=233)
Efficacy:
  • CR: 4% vs. 1%
  • ORR: 31% vs. 4%
  • Median DoR: 6.3 vs. 3.6 mos
  • Median PFS: 5.6 vs. 1.7 mos (HR: 0.41 [0.32-0.52])
  • Median OS: 12.1 vs. 6.7 mos (HR: 0.48 [0.38-0.59])
Safety:
  • Grade >=3 AEs: neutropenia (51% vs. 33%), febrile neutropenia (6% vs. 3%), diarrhea (10% vs. 1%)

N Engl J Med 2021;384:1529-41.

Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

https://doi.org/10.1056/NEJMoa2028485

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More